Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia

doi:10.4254/wjh.v8.i6.331

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7868)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

338

WORD

294

HTML

2671

Figures (1-3)

138

Tables (1-5)

151

Sum=3592

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

449

Download

873

Sum=1322

Publishing Process of This Article

Item

Count

Browse

1029

Download

1925

Sum=2954

Feb 28, 2016 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Hepatol. Feb 28, 2016; 8(6): 331-339
Published online Feb 28, 2016. doi: 10.4254/wjh.v8.i6.331

Table 5 Comparison of virologic response rates between Russian patients and western patients receiving boceprevir-based triple therapy in the serine protease inhibitor therapy 2 and retreatment with hepatitis C virus serine protease inhibitor boceprevir and pegIntron/rebetol 2 studies n (%)

	Russian patients		SPRINT-2		RESPOND-2
	RGT of BOC	PR	RGT of BOC	PR	RGT of BOC	PR
TN
EOT	89/97 (91.8)	33/48 (68.8)	277/366 (76)	191/363 (53)	-	-
SVR	76/97 (78.4)	27/48 (56.3)	242/366 (66)	137/363 (38)	-	-
Relapse	13/89 (14.6)	6/33 (18.2)	24/265 (9)	39/176 (22)	-	-
TE
EOT	50/62 (80.6)	13/30 (43.3)	-	-	114/162 (70.4)	25/80 (31)
SVR	43/62 (69.4)	9/30 (30)	-	-	107/161 (66)	17/80 (21)
Relapse	7/48 (14.6)	3/12 (25.0)	-	-	14/121 (12)	8/25 (32)

BOC: Boceprevir; EOT: End of treatment response; PR: Peginterferon/ribavirin; RESPOND-2: Retreatment with hepatitis C virus serine protease inhibitor boceprevir and pegIntron/rebetol 2 study; RGT: Response-guided therapy; SPRINT-2: Serine protease inhibitor therapy 2 study; SVR: Sustained virologic response; TE: Treatment experienced; TN: Treatment naive.

Citation: Isakov V, Nikitin I, Chulanov V, Ogurtsov P, Lukyanova E, Long J, Wahl J, Helmond FA, The P08160 Trial Investigators. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol 2016; 8(6): 331-339
URL: https://www.wjgnet.com/1948-5182/full/v8/i6/331.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i6.331